Xenon Pharmaceuticals Inc
NASDAQ:XENE
Intrinsic Value
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of XENE.
Fundamental Analysis
Balance Sheet Decomposition
Xenon Pharmaceuticals Inc
| Current Assets | 645m |
| Cash & Short-Term Investments | 638.1m |
| Receivables | 874k |
| Other Current Assets | 6m |
| Non-Current Assets | 319.8m |
| Long-Term Investments | 292.8m |
| PP&E | 18.8m |
| Other Non-Current Assets | 8.2m |
| Current Liabilities | 27.3m |
| Accounts Payable | 8.9m |
| Accrued Liabilities | 18.3m |
| Non-Current Liabilities | 9.6m |
| Other Non-Current Liabilities | 9.6m |
Earnings Waterfall
Xenon Pharmaceuticals Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-214.1m
USD
|
|
Operating Income
|
-214.1m
USD
|
|
Other Expenses
|
31.7m
USD
|
|
Net Income
|
-182.4m
USD
|
Free Cash Flow Analysis
Xenon Pharmaceuticals Inc
XENE Profitability Score
Profitability Due Diligence
Xenon Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Xenon Pharmaceuticals Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
XENE Solvency Score
Solvency Due Diligence
Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XENE Price Targets Summary
Xenon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for XENE is 59.26 USD with a low forecast of 50.5 USD and a high forecast of 68.25 USD.
Ownership
XENE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
XENE Price
Xenon Pharmaceuticals Inc
| Average Annual Return | 46.53% |
| Standard Deviation of Annual Returns | 48.1% |
| Max Drawdown | -54% |
| Market Capitalization | 3B USD |
| Shares Outstanding | 75 430 000 |
| Percentage of Shares Shorted | 3.67% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Burnaby, British Columbia and currently employs 149 full-time employees. The company went IPO on 2014-10-17. The firm is engaged in developing therapeutics in patients with neurological disorders. Its product candidates include XEN1101, XEN496 and XEN007. Its partnered programs include NBI-921352 and FX301. Its XEN1101is a Kv7 potassium channel modulator for the treatment of epilepsy and other neurological disorders. Its XEN496 is a Kv7 potassium channel modulator for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Its XEN007 is a CNS-acting Cav2.1 and T-type calcium channel modulator that for the treatment of childhood absence epilepsy (CAE). The NBI-921352 is a Nav1.6 sodium channel inhibitor to treat pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE) and other indications, including adult focal epilepsy.
You don't have any saved screeners yet
